This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Integra (IART) Down 4.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold On to Integra LifeSciences Stock
by Zacks Equity Research
Investor confidence is still high on growth prospects of Integra LifeSciences (IART).
Integra LifeSciences Rides on Product Launch, Faces Rivalry
by Zacks Equity Research
Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.
Integra LifeSciences (IART) Q1 Earnings Beat, Margins Rise
by Zacks Equity Research
Integra LifeSciences' (IART) quarterly performance is majorly hurt by the company's exit from the transition services agreements covering Western Europe.
Integra LifeSciences (IART) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra's Product Launch a Growth Catalyst, Rivalry Rife
by Zacks Equity Research
Product launches and a sales force performance upgrade are likely to boost rapid organic growth for Integra LifeSciences (IART) in the second half of 2019.
Why Is Integra (IART) Down 0.5% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra's Duragen Secures Japanese Nod to Drive Global Growth
by Zacks Equity Research
Despite facing adverse foreign exchange volatility across its international business, Integra LifeSciences (IART) can successfully eye certain key developments on foreign shores.
Integra Rides on Channel Expansion Strategy, New Alliances
by Zacks Equity Research
Integra's (IART) success with its channel expansion strategy and Codman integration buoys investors' optimism on the stock.
Integra's (IART) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Strength in the U.S. Codman Specialty Surgical business drives Integra LifeSciences' (IART) top line in Q4.
Integra LifeSciences (IART) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 4.84% and 0.56%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio
by Zacks Equity Research
The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.
Integra (IART) Rises 5% on Robust Preliminary Q4 Results
by Zacks Equity Research
Integra's (IART) total Q4 revenues are likely to be at the upper end of its prior guided range.
Integra Rides on Global Prospects, Hurt by Escalating Costs
by Zacks Equity Research
Integra LifeSciences (IART) aims at investment openings in the Asian market for a faster business boost than in the United States and also to flourish specific parts of its international businesses.
Integra (IART) Down 2.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra's (IART) Margin Pressure Hurts, Global Prospects High
by Zacks Equity Research
Massive gross margin declines induced by mounting costs are a major downside for Integra LifeSciences (IART).
Integra (IART) Q3 Earnings Meet Estimates, Revenue View Dips
by Zacks Equity Research
Integra LifeSciences' (IART) success with its channel expansion policy and Codman acquisition raise optimism on the stock.
Integra LifeSciences (IART) Matches Q3 Earnings Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 0.00% and -1.28%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Q3 Earnings on Oct 31: BAX, MASI & More
by Zacks Equity Research
Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.
Integra LifeSciences (IART) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
Integra Lifesciences Picked for Healogics iSupply Program
by Zacks Equity Research
Integra Lifesciences' (IART) selection as a key provider for cellular-based tissue products within Healogics' new iSupply program to boost the top line.
Why Is Integra (IART) Down 2.7% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Integra LifeSciences Codman Arm Strong, Competition Rife
by Zacks Equity Research
Integra LifeSciences' (IART) progress within its channel expansion strategy and Codman integration buoys investors' optimism on the stock.